Yagci Tamer, Cetin Metin, Ercin Pelin Balcik
Department of Molecular Biology and Genetics, Gebze Technical University, 41400, Cayirova, Kocaeli, Turkey.
J Gastrointest Cancer. 2017 Sep;48(3):241-245. doi: 10.1007/s12029-017-9960-7.
Hepatocellular carcinoma is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Only a small proportion of patients benefit from curative treatment and the prognosis is very poor for the majority of cases due to late presentation, resistance to chemotherapy and high recurrence rate. In recent years, progress in stem cell biology allowed us to explain that hierarchically organized cancer stem cells (CSCs) drive histological and functional heterogeneity of hematological malignancies and solid tumors.
Also referred to as tumor-initiating cells, CSCs have been isolated from both hepatocellular carcinoma (HCC) cell lines and primary tumors by using hepatic progenitor markers. Although there is still no consensus on cancer stem cell phenotype in HCC, single or combined use of CSC markers defines a minor population of tumor cells with the capacity of self-renewing and the ability to recapitulate the original tumor heterogeneity.
This review focuses on the biological features of CSCs and their potential as diagnostic/prognostic tools and therapeutic targets in HCC.
肝细胞癌是全球最常见的癌症之一,也是癌症相关死亡的第二大主要原因。只有一小部分患者能从根治性治疗中获益,由于就诊时已属晚期、对化疗耐药以及高复发率,大多数病例的预后很差。近年来,干细胞生物学的进展使我们能够解释,分层组织的癌症干细胞(CSC)驱动血液系统恶性肿瘤和实体瘤的组织学及功能异质性。
CSC也被称为肿瘤起始细胞,已通过使用肝祖细胞标志物从肝细胞癌(HCC)细胞系和原发性肿瘤中分离出来。尽管对于HCC中癌症干细胞的表型仍未达成共识,但单一或联合使用CSC标志物可定义一小部分具有自我更新能力且能够重现原始肿瘤异质性的肿瘤细胞。
本综述重点关注CSC的生物学特性及其作为HCC诊断/预后工具和治疗靶点的潜力。